Escherichia coli belonging to the worldwide emerging epidemic clonal group o25b/ST131: Risk factors and clinical implications

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 809-814

  López Cerero, Lorena ^a,b   Navarro, María Dolores ^a   Bellido, Mar ^a   Martín Peña, Almudena ^c   Viñas, Laura ^c   Cisneros, José Miguel ^b,c   Gómez Langley, Sara Louise ^d   Sánchez Monteseirín, Herminia ^d   Morales, Isabel ^a,b   Pascual, Alvaro ^a,b,e   Rodríguez Baño, Jesús ^a,b,e  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d Centro de Salud Esperanza Macarena   (Spain)

^e UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Antimicrobial resistance; Clinical outcomes; Extended spectrum lactamases

Indexed keywords

BETA LACTAMASE;

ADOLESCENT; ADULT; AGED; CLASSIFICATION; ENZYMOLOGY; EPIDEMIC; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENOTYPE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; MOLECULAR TYPING; PATHOLOGY; RISK FACTOR; SECRETION (PROCESS); SEPSIS; SPAIN; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BETA-LACTAMASES; EPIDEMICS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TYPING; RISK FACTORS; SEPSIS; SPAIN; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84894028219     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt405     Document Type: Article

References (30)

1. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M b-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010; 35: 316-21.
2. Johnson JR, Nicolas-Chanoine MH, DebRoy C et al. Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. Emerg Infect Dis 2012; 18: 598-607.
3. Johnson JR, Johnston B, Clabots C et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51: 286-94.
4. Blanco J, Mora A, Mamani R et al. National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. J Antimicrob Chemother 2011; 66: 2011-21.
5. Platell JL, Johnson JR, Cobbold RN et al. Multidrug-resistant extraintestinal pathogenic Escherichia coli of sequence type ST131 in animals and foods. Vet Microbiol 2011; 153: 99-108.
6. Platell JL, Cobbold RN, Johnson JR et al. Commonality among fluoroquinolone-resistant sequence type ST131 extraintestinal Escherichia coli isolates from humans and companion animals in Australia. Antimicrob Agents Chemother 2011; 55: 3782-7.
7. Dhanji H, Murphy NM, Akhigbe C et al. Isolationoffluoroquinolone-resistant O25b:H4-ST131 Escherichia coli with CTX-M-14 extended-spectrum b-lactamase fromUK river water. J Antimicrob Chemother 2011; 66: 512-6.
8. Banerjee R, Johnston B, Lohse C et al. Escherichia coli type 131 is a dominant, antimicrobial resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol 2013; 34: 361-9.
9. Rodríguez-Ban{ogonek}o J, Alcalá JC, Cisneros JM et al. Community infections caused by extended-spectrum b-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168: 1897-902.
10. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-83.
11. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference. Crit Care Med 2003; 31: 1250-6.
12. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32.
13. Clermont O, Dhanji H, Upton M et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009; 64: 274-7.
14. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000; 66: 4555-8.
15. Doumith M, Day MJ, Hope R et al. Improved multiplex PCR strategy for rapid assignment of the four major Escherichia coli phylogenetics groups. J Clin Microbiol 2012; 50: 3108-10.
16. López-Cerero L, Bellido MD, Serrano L et al. Escherichia coli O25b:H4/ ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. Enferm Infecc Microbiol Clin 2013; 31: 385-8.
17. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI,Wayne, PA, USA, 2012.
18. Coque TM, Novais A, Carattoli A et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum b-lactamase CTX-M-15. Emerg Infect Dis 2008; 14: 195-200.
19. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout Vet al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61: 273-81.
20. Leflon-Guibout V, Blanco J, Amaqdouf K et al. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 2008; 46: 3900-5.
21. Adams-Sapper S,Diep BA, Perdreau-Remington F et al. Clonal composition and community clustering of drug-susceptible and -resistant Escherichia coli isolates from bloodstream infections. Antimicrob Agents Chemother 2013; 57: 490-7.
22. Chung HC, Lai CH, Lin JN et al. Bacteremia caused by extendedspectrum-b-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, andmortality. Antimicrob Agents Chemother 2012; 56: 618-22.
23. Adler A, Gniadkowski M, Baraniak A et al. Transmission dynamics of ESBL-producing Escherichia coli clones in rehabilitation wards at a tertiary care centre. Clin Microbiol Infect 2012; 18: E497-505.
24. Novais A, Pires J, Ferreira H et al. Characterization of globally spread Escherichia coli ST131 isolates (1991 to 2010). Antimicrob Agents Chemother 2012; 56: 3973-6.
25. Dhanji H, Doumith M, Rooney PJ et al. Molecular epidemiology of fluoroquinolone-resistant ST131 Escherichia coli producing CTX-M extendedspectrum b-lactamases in nursing homes in Belfast, UK. J Antimicrob Chemother 2011; 66: 297-303.
26. Ben-Ami R, Rodríguez-Ban{ogonek}o J, Arslan H et al. A multinational survey of risk factors for infection with extended-spectrum b-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49: 682-90.
27. Johnson JR, Porter SB, ZhanelG et al. Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect Immun 2012; 80: 1554-62.
28. Rodríguez-Ban{ogonek}o J, Mingorance J, Fernández-Romero N et al. Outcome of bacteraemia due to extended-spectrumb-lactamase-producing Escherichia coli: impact ofmicrobiological determinants. J Infect 2013; 67: 27-34.
29. Williamson DA, Roberts SA, Paterson DL et al. Escherichiacoli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistantsequencetype131asamajorcausativepathogen. Clin Infect Dis 2012; 54: 1406-12.
30. Matsumura Y, Yamamoto M, Nagao M et al. Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum-b-lactamase-producing Escherichia coli in Japan. J Antimicrob Chemother 2012; 67: 2612-20.